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Summary Neurologic complications after allogeneic 
hematopoietic stem cell transplantation (HSCT) are 
rare but poorly understood. We present a case report of 
a 57-year-old-male patient who was diagnosed in 2009 
with acute myeloid leukemia (AML). He received two 
standard induction chemotherapies, as well as a follow-
ing consolidation. Six months later, an allogeneic HSCT 
was performed. Shortly after HSCT the patient developed 
progressive polyneuropathy of the lower legs and hypo-
esthesia. Five months later a severe dementia followed. 
All images of the brain and spine showed no specific 
pathologies. High dose corticosteroids and immunoglob-
ulins did not improve the neurologic symptoms. Due to 
severe worsening of the neuropsychiatric status and the 
clinical presentation, chronic inflammatory demyelin-
ating polyneuropathy (CIDP) was suspected. Therefore, 
the patient received ten cycles of plasmapheresis. The 
patient showed a significant improvement of the neu-
ropsychiatric symptoms and cognitive status. CONCLU-
SIONS: Immune mediated neuropathies after allogeneic 
HSCT, such as CIDP, have great variability in symptoms 
and presentation and are challenging to diagnose and 
treat. Plasmapheresis is a safe and efficient treatment for 
patients with unclear persisting autoimmune neuropa-
thy after HSCT.
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Introduction
Neurologic complications ,such as chronic inflamma-
tory demyelinating polyneuropathy (CIDP), myasthenia 
gravis or Guillain–Barré syndrome, after allogeneic HSCT 
are rarely seen but have great variability in symptoms 
and presentation and are challenging to diagnose and 
treat [1–3]. Plasmapheresis is established as effective and 
should be offered as short-term management of CIDP [4, 
5] (Class I studies, level A).
Case report
A 56-year-old-male patient was diagnosed in 2009 with 
an acute myeloid leukemia (AML; French–American–
British FAB: M1, cytogentics: FLT3 neg, mDx Hema 
Vision Multiplex RT-PCR neg., Tryptase pos.) Initially he 
received standard induction chemotherapy with cytara-
bine, daunorubicin, etoposide, and a second induction 
chemotherapy with MIDAC (mitoxantrone, cytarabine) 
after blast cell persistance. The following consolida-
tion was similar to the second induction chemotherapy 
(MIDAC). Six months later an HLA-identical unrelated 
donor was available. After conditioning chemotherapy, 
an allogeneic hematopoietic stem cell transplantation 
(HSCT) was performed. Conditioning chemotherapy 
consisted of Amsacrin 100  mg/m2, Fludarabine 30  mg/
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m2, and Cytarabine 2000  mg/m2 from days − 12 to − 9; 
after 3 days of rest, 4 Gy total-body irradiation (TBI) on 
day − 5; Thymoglobuline 2.5  mg/kg and Cyclophospha-
mide 60 mg/m2 on days − 4 and − 3. He received 6.3 × 106/
kg body weight peripheral blood stem cells from an 
unrelated donor on June 17, 2009 [6]. Cylosporin A (CsA), 
along with mycophenolatmofetil, was used as an immu-
nosuppressant. Leukocyte engraftment was observed 
on day + 14 (> 0.5 G/l) and platelets on day + 8 (> 20 G/l). 
During transplantation he experienced a bacterial infec-
tion with staphylococcus epidermis on day 1. On day 15 
he developed grade III acute graft-versus-host disease 
(GvHD) of the skin, which was treated with high-dose 
corticosteroids 2 mg/kg and resolved on day 45.
Shortly after allogeneic HSCT and after appearance of 
acute GvHD (August 10, 2009, day + 58) the patient devel-
oped progressive tremor and disorientation while expe-
riencing a cytomegalovirus (CMV) reactivation. Other 
medical reasons, such as thrombotic thrompocytopenic 
purpura (TTP) and drug toxicities were ruled out. CMV 
reactivation was successfully treated with ganciclovir 
for 14 days. Polymorphism chain reaction (PCR) tests 
showed negative results for CMV. However, neurological 
symptoms were still present, and more tests were run. 
Magetic Resonance Imaging (MRI) and liquor tests were 
negative, CsA was discontinued. Shortly after, the patient 
presented with progressive polyneuropathy of the lower 
legs and hypoesthesia on both feet.
Five months later the patient additionally developed 
a severe dementia with changes in personality and uri-
nary retention. MRI and computed tomographies (CT) of 
the brain and spine showed no specific pathologies, the 
positron-emission tomography (PET) CT was also nega-
tive. The spinal fluid analysis showed slightly elevated 
cells with high protein levels and lymphocytic cells. All 
viral and bacterial diagnostics in the liquor were nega-
tive. The somatosensory evoked potentials (SSEP) were 
pathologic in concern of the lower right extremity. First-
line therapy consisted of high dose corticosteroids and 
immunoglobulins. Due to severe worsening of the neu-
ropsychiatric status and the results that were highly sus-
picious for chronic inflammatory polyneuropathy, the 
patient received ten cycles of plasmapheresis, which 
started on December 31, 2009.
During plasmapheresis, the patient showed a signifi-
cant improvement of the neuropsychiatric symptoms. 
The cognitive status improved to almost normal.
During the follow-up period over the last 3 years, the 
patient is still in good health, the cognitive status is nor-
mal. There is no sign of neuromotoric deficiency. In June 
2012 he again developed muscle cramps in the lower left 
limb. The electromyogram and muscle enzymes were 
negative. He received another cycle of immunoglobu-
lins (2 g/kg/BW) for 5 days. The muscle cramps are still 
present but lower in frequency and the condition is 
improving.
He is even able to do physical workout again. Consid-
ering that the patient was running marathons this was an 
important improvement in quality of life. The last neu-
rological examination did not show any motoric defi-
ciencies. Moreover, he is still in complete hematologic 
remission of the AML.
Discussion
Neurological complications following allogeneic HSCT 
are described in about 10–20 % in the literature, but 
immune-mediated neuropathies such as CIDP or Guil-
lain–Barré syndrome are rare with an incidence of about 
1–4 % [7, 8]. There are reports that the onset of these neu-
ropathies correlates with the event of acute or chronic 
GvHD. Other theories suspect that the GvHD targets 
the nervous tissue itself [9]. Clinical features have great 
variability, and distinguishing acute-onset CIDP from 
Guillain–Barre syndrome is challenging. Similar to our 
patient, typical clinical presentations were paresthesia, 
progressive muscle weakness, sensory dysfunction, and 
impaired balance. The onset of these symptoms was 
shortly after development of acute GvHD of the skin 
on day 45 after allogeneic HSCT. Usually the disease 
responds quite well to corticosteroids or high dose immu-
noglobulins. In our patient the symptoms worsened and 
another symptom, namely, decreased cognitive potential 
(dementia) appeared. Decreased cognitive potential and 
aggressive behavior are typical signs of dementia but not 
CIDP. One could discuss that this was a direct symptom 
of GvHD of the nervous tissue or brain tissue.
The pathogenesis that causes autoimmunity to ner-
vous tissue such as pathogenic autoantibodies or a single 
triggering antigen is not yet known. Various infections 
have been implicated as triggering events but not yet 
proven [10]. In our patient a CMV reactivation happened 
shortly before the beginning of neurologic symptoms.
Plasmapheresis, which removes pathogenic antibod-
ies or circulating immune factors have shown to be effec-
tive in treating CIDP in controlled studies [4, 5]. In our 
patient not only the peripheral neurologic symptoms 
but also the neuropsychiatric symptoms presenting as 
dementia resolved. After several years of follow-up our 
patient had no relapse of CIDP, had normal cognitive 
function and is still in complete hematologic remission.
In conclusion, CIDP is a rare complication after HSCT 
and is very often associated with acute GvHD. Plasma-
pheresis should be considered as an option in patients 
who do not respond to corticosteroids or immunoglobu-
lins. Plasmapheresis provides a safe and quick relief to 
majority of patients with CIDP.
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